中度心血管疾病风险的成人2型糖尿病患者开始非胰岛素降糖治疗后发生严重低血糖的风险

Q2 Medicine

Clinical Diabetes Pub Date : 2024-09-13 eCollection Date: 2025-01-01 DOI:10.2337/cd24-0007

Rozalina G McCoy, Kavya Sindhu Swarna, Joshua J Neumiller, Eric C Polley, Yihong Deng, Mindy M Mickelson, Jeph Herrin

{"title":"中度心血管疾病风险的成人2型糖尿病患者开始非胰岛素降糖治疗后发生严重低血糖的风险","authors":"Rozalina G McCoy, Kavya Sindhu Swarna, Joshua J Neumiller, Eric C Polley, Yihong Deng, Mindy M Mickelson, Jeph Herrin","doi":"10.2337/cd24-0007","DOIUrl":null,"url":null,"abstract":"In this emulated comparative effectiveness target trial of glucagon-like peptide 1 (GLP-1) receptor agonist, sodium-glucose cotransporter 2 (SGLT2) inhibitor, dipeptidyl peptidase 4 (DPP-4) inhibitor, and sulfonylurea therapy among adults with type 2 diabetes at moderate cardiovascular disease risk, sulfonylurea use was associated with a significantly higher risk of hypoglycemia requiring emergency department or hospital care than treatment with DPP-4 inhibitors, GLP-1 receptor agonists, or SGLT2 inhibitors. This consideration can guide the choice of glucose-lowering therapy in this highly prevalent patient population, in whom avoidance of hypoglycemia is important, yet among whom the risk of severe hypoglycemia has not been examined previously.","PeriodicalId":39894,"journal":{"name":"Clinical Diabetes","volume":"43 1","pages":"59-70"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739335/pdf/","citationCount":"0","resultStr":"{\"title\":\"Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk.\",\"authors\":\"Rozalina G McCoy, Kavya Sindhu Swarna, Joshua J Neumiller, Eric C Polley, Yihong Deng, Mindy M Mickelson, Jeph Herrin\",\"doi\":\"10.2337/cd24-0007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this emulated comparative effectiveness target trial of glucagon-like peptide 1 (GLP-1) receptor agonist, sodium-glucose cotransporter 2 (SGLT2) inhibitor, dipeptidyl peptidase 4 (DPP-4) inhibitor, and sulfonylurea therapy among adults with type 2 diabetes at moderate cardiovascular disease risk, sulfonylurea use was associated with a significantly higher risk of hypoglycemia requiring emergency department or hospital care than treatment with DPP-4 inhibitors, GLP-1 receptor agonists, or SGLT2 inhibitors. This consideration can guide the choice of glucose-lowering therapy in this highly prevalent patient population, in whom avoidance of hypoglycemia is important, yet among whom the risk of severe hypoglycemia has not been examined previously.\",\"PeriodicalId\":39894,\"journal\":{\"name\":\"Clinical Diabetes\",\"volume\":\"43 1\",\"pages\":\"59-70\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739335/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Diabetes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2337/cd24-0007\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2337/cd24-0007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

在这项模拟胰高血糖素样肽1 （GLP-1）受体激动剂、钠-葡萄糖共转运蛋白2 （SGLT2）抑制剂、二肽基肽酶4 （DPP-4）抑制剂和磺酰脲治疗在中度心血管疾病风险的成人2型糖尿病患者中的有效性比较试验中，磺酰脲的使用与需要急诊或医院护理的低血糖风险显著高于DPP-4抑制剂、GLP-1受体激动剂的治疗相关。或SGLT2抑制剂。这一考虑可以指导在这一高度流行的患者人群中选择降糖治疗，在这一人群中，避免低血糖是重要的，但在这一人群中，严重低血糖的风险以前没有被检查过。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk.

In this emulated comparative effectiveness target trial of glucagon-like peptide 1 (GLP-1) receptor agonist, sodium-glucose cotransporter 2 (SGLT2) inhibitor, dipeptidyl peptidase 4 (DPP-4) inhibitor, and sulfonylurea therapy among adults with type 2 diabetes at moderate cardiovascular disease risk, sulfonylurea use was associated with a significantly higher risk of hypoglycemia requiring emergency department or hospital care than treatment with DPP-4 inhibitors, GLP-1 receptor agonists, or SGLT2 inhibitors. This consideration can guide the choice of glucose-lowering therapy in this highly prevalent patient population, in whom avoidance of hypoglycemia is important, yet among whom the risk of severe hypoglycemia has not been examined previously.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Diabetes Medicine-Internal Medicine

CiteScore

4.30

自引率

0.00%

发文量

期刊介绍： The mission of Clinical Diabetes is to provide primary care providers and all clinicians involved in the care of people with diabetes with information on advances and state-of-the-art care for people with diabetes. Clinical Diabetes is also a forum for discussing diabetes-related problems in practice, medical-legal issues, case studies, digests of recent research, and patient education materials.